Who is Ronald D. Sugar and why is he joining Amgen's Board?

Ronald D. Sugar is a seasoned executive with a strong background in aerospace and defense, notably as the former Chairman and CEO of Northrop Grumman Corporation. His appointment to Amgen's Board of Directors is intended to bring his strategic leadership experience to the company. He will also serve on key committees, including Compensation and Management Development, and Governance and Nominating.

What is the impact of the amendment to the Executive Nonqualified Retirement Plan?

The amendment corrects a drafting error in the definition of "Retirement Date" for interest crediting purposes under the plan. It lowers the age requirement from 60 to 55, provided the participant has completed 10 years of active employment. This change accelerates the date at which Messrs. Morrow and Perlmutter will have their "Retirement Date" considered for interest crediting.

Are there any financial implications for existing shareholders related to Dr. Sugar's appointment?

The filing details Dr. Sugar's compensation as a non-employee director, which includes a pro-rated annual retainer, per-meeting attendance fees, reimbursement of expenses, and equity grants (stock options and restricted stock units). While this represents an increase in director compensation costs, it is standard practice for new board members and is not expected to have a material adverse impact on existing shareholders given the company's size.

Are there any other significant changes reported in this 8-K?

This 8-K primarily focuses on the board appointment and the retirement plan amendment. No other significant corporate events, financial results, or operational changes were reported in this specific filing.

AMGN 8-K: Leadership Changes

Summary

Amgen Inc. (AMGN) filed an 8-K report on July 22, 2010, announcing significant changes to its Board of Directors and an amendment to an executive retirement plan. The most notable event is the appointment of Ronald D. Sugar as a new director, effective immediately. Dr. Sugar brings extensive experience, having previously served as Chairman and CEO of Northrop Grumman Corporation and holding various leadership roles in other major corporations. Additionally, the Compensation and Management Development Committee approved an amendment to the Amgen Inc. Executive Nonqualified Retirement Plan. This amendment corrects a drafting error by lowering the age requirement for determining a "Retirement Date" for interest crediting purposes from 60 to 55, provided 10 years of active employment is met. This change specifically impacts the "Retirement Dates" for Messrs. Morrow and Perlmutter, accelerating their eligibility for interest crediting under the plan.

Key Highlights

1Appointment of Ronald D. Sugar to Amgen's Board of Directors, effective July 22, 2010.
2Dr. Sugar's extensive leadership background includes former Chairman and CEO of Northrop Grumman Corporation.
3Dr. Sugar will serve on the Compensation and Management Development Committee and the Governance and Nominating Committee.
4No related-party transactions were disclosed between Dr. Sugar and Amgen.
5Amendment to the Amgen Inc. Executive Nonqualified Retirement Plan to correct a "Retirement Date" definition.
6The amendment lowers the age requirement for "Retirement Date" from 60 to 55 (with 10 years of service), impacting Messrs. Morrow and Perlmutter.
7The amendment accelerates the "Retirement Date" for Mr. Morrow to January 19, 2011, and for Dr. Perlmutter to January 7, 2011.

AMGEN INC 8-K Report, Executive Changes (Jul 23, 2010)

Summary

Key Highlights

Frequently Asked Questions